University of Colorado

University of Vermont and State Agricultural College

Other

The Texas A&m University System

Scott & White Healthcare

Martha Karen Newell

Evan Newell

Richard Tobin

Ian N Askill

Javin Cedric Pierce

William E Crisp

Elizabeth Villalobos-Menuey

Cassie L Harvey

Joshua Hunter Cabrera

Susannah K Rogers

Elizabeth Villobos-Menvey

Elizabeth Villobos-Menuey

Sandy Berry-Lowe

Sandra L Berry-Lowe

Odbert Triplett

Compositions and methods for enhancing secretion of oils from oil producing cells are described herein. In particular, secretion of oils is enhanced by treating the cells with herbicides. The oils generated according to the invention may be useful, for example, in the production of biofuels.

Methods and products for generating oils

Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-D-glucose and anti-VEGF antibodies. The systems and methods of the invention may be used to treat drug-resistant or multi-drug resistant cancers.

Methods and products for treating proliferative diseases

The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.

Competitive inhibitors of invariant chain expression and/or ectopic clip binding

The disclosure relates to methods for treating disorders of the mucosal tract such as the gastrointestinal system by targeting CLIP molecules. The methods are based on that CLIP in the groove of MHC class I or II molecules of the cells lining the mucosal surfaces of the body, such as the gastrointestinal tract, provides protection from MHC Class II or MHC class I mediated cell death, and therefore are useful for treating, inhibiting the development of a multitude of illnesses and conditions of the mucosal tract, including autoimmune disease.

Method of treating inflammatory bowel disease by administering a clip-inducing agent

The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject.

Methods of modulating immune function

The invention relates to methods and products for producing fatty acids by manipulating metabolic function in plants and fungus. The fatty acids generated according to the invention may be useful in the production of biofuels.

Compositions and methods for promoting fatty acid production in plants

The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof.

Methods for treating cancer using combination therapy

Methods and compositions for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using combination of compounds, or a bifunctional compound, that inhibits both fatty acid metabolism and glycolysis. In particular, the invention combines or links a glycolysis inhibitor that is, or that is derived from, hypoglycin A (also referred to as hypoglycine A) and a fatty acid metabolism inhibitor. Preferably, the invention provides bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a hypoglycin A derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of hypoglycin A.

Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition

Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.

Method of treating drug-resistant cancer

The invention is based in part on the discovery that uncoupling proteins (UCPs) are expressed in the plasma membrane of rapidly dividing cells but not of growth arrested, chemotherapy resistant cells. It has also been found according to the invention that UCP is expressed in the lysosomal membrane under certain metabolic conditions. Thus the invention is methods, products, screening assays and kits relating to the manipulation of UCP expression within cellular and intracellular membranes.

Methods and products for manipulating uncoupling protein expression

Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor

The present invention generally relates to systems and methods for treating inflammatory and proliferative diseases, and wounds, using a combination of (1) fatty acid metabolism inhibitors and (2) glycolytic inhibitors and/or UCP and/or Fas inhibitors or antibodies. More particularly, the invention combines an oxirane carboxylic acid compound, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers (i.e., cancers resistant to conventional cancer drug therapies).

Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors

The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays.

Methods and products related to metabolic interactions in disease

The invention relates to methods and products for manipulating plant metabolism and resistance to infection.

Growing community of inventors

Colorado Springs, CO, United States of America

Martha Karen Newell